Article and Video CATEGORIES

Cancer Journey

Search By

Alice T. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School. She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr.

Lung Cancer Video Library - Changing Landscape of First-Line Treatment of ALK-positive Advanced NSCLC
Thu, 04/12/2018 - 15:48
Author
Alice Shaw, MD, Ph.D, GRACE Faculty

 

 

 

 

The Changing Landscape of First-Line Treatment of ALK-Positive Advanced NSCLC Presented by Alice Shaw, MD, PhD Associate Professor, Medicine, Harvard Medical School Attending Physician, Thoracic Cancer Program, Massachusetts General Hospital TRANSCRIPT 
 

My name is Alice Shaw, I am director of the Center for Thoracic Cancers at Massachusetts General Hospital in Boston.  Since 2011, the first generation ALK inhibitor Crizotinib has been the standard first-line therapy for patients who are newly diagnosed with ALK-positive lung cancer. The efficacy with Crizotinib is very significant, certainly better than with standard platinum combination chemotherapy. We typically see response rates over 70% with first-line Crizotinib and a median progression-free survival close to 11 months. So very good activity of Crizotinib in the first-line setting. However, we all know that patients will ultimately relapse on first-line Crizotinib and we have been working very hard the last several years to develop better options for patients who are newly diagnosed with advanced ALK-positive lung cancer. Over the last several years specifically, we now have randomized trails comparing second-generation inhibitors to standard of care. I would say the most important of these studies are the ALEC studies: The J-ALEC study which was conducted in Japan and the global ALEC study which was conducted worldwide. The ALEC studies are important because they compared for the very first time first-line Alectinib with first-line Crizotinib. These were randomized studies randomizing patients one-to-one to receive either Alectinib or Crizotinib as their first-line therapy and the primary endpoint in these studies was progression-free survival. Now these were separate studies, but they are remarkably similar on analysis of the data. In both studies Alectinib was shown to be significantly superior to Crizotinib over doubling the median PFS (progression-free survival).  
As an example, in the Global ALEC study the median progression-free survival with first-line Alectinib was about 26 months based on independent review and that’s as compared to 11 months with Crizotinib. And as I said, very very similar results were seen on longer follow-up of the Japanese or JALEC study. We also saw very high response rates with Alectinib in both studies and importantly what we saw in both studies is that the intracranial activity of Alectinib is really quite remarkable compared to the standard of care Crizotinib. So, what we observed is that Alectinib was able to treat and control CNS metastases better than Crizotinib and importantly was able to decrease the accumulative incidence of CNS metastases compared to Crizotinib. So, in a way Alectinib was able to prevent the development of CNS metastases and this is a very important point for patients.  The last thing I’ll note about these two randomized studies is that in both cases it did appear that Alectinib was overall better tolerated than Crizotinib. Crizotinib already is a relatively well tolerated drug but Alectinib seemed to have fewer serious side effects associated with it. The most common side effects seen with Alectinib tend to be mild such as fatigue, constipation, edema, and muscle aches.  Overall, Alectinib was not only more efficacious than Crizotinib both in terms of systemic and intracranial activity but overall was somewhat better tolerated than Crizotinib as well. These two studies now have really changed the treatment landscape for patients who are newly diagnosed with advanced ALK-positive lung cancer. These patients just a few months ago would have received Crizotinib in the U.S. as their first therapy and I think now with the J-ALEC and ALEC studies both published that we’ve now moved toward using Alectinib as our preferred first-line therapy for patients with advanced ALKpositive lung cancer.  
 


 We would like to thank the following companies for their support of this program

 

                

 

 

                        

 

 
 

 

 


  

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Terapias Dirigidas de Cáncer de Pulmón 2023
Video
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras. En esta serie de videos los Doctores Fernando Diaz, Luis Raez, Luis Corrales, Estelamari Rodriguez y Alberto Chiappori presentan el Panel de Discusión donde hablan sobre temas relevantes del cáncer de pulmón. 
Image
Terapias Dirigidas de Cáncer de Pulmón 2023
Video
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras. En esta serie de videos los Doctores Fernando Diaz, Luis Raez, Luis Corrales, Estelamari Rodriguez y Alberto Chiappori presentan el Panel de Discusión donde hablan sobre temas relevantes del cáncer de pulmón. 
Image
September 2023 Blood Cancer OncTalk
Article
The September 2023 Blood Cancer OncTalk has now ended.  Videos are available OnDemand! The full unedited versions of the September 2023 Blood Cancer OncTalk, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.   The full videos are available on our YouTube channel via this link:  https://youtube.com/playlist?list=PLWsyUmdjLXhG4km7yALHmLjQSeUQg-36x

Forum Discussions

Stan - Thank you once again for your kind words.  Thank you as well for your donation.  As you know, your donation helps us to exist and continue to fulfill our...

Hi Stan, It's good to hear your voice and know your cheesecakes are still making the rounds.  Though I'm sure startling, I imagine some of those little pockets of the house...

Hi Rutbats,  Welcome to GRACE and thanks for the kind words. 

 

We can't say what you should or shouldn't do and I can't say why your RA doc made their...

Thank you very much for your quick answer, Janine.

I have an appointment with a pulmonologist in 10 days. I will summarize the conversation with him here, so that other people...

Glad to know you're moving forward with a pulmonologist.  The more you know the better the conversation with your pulmonologist.  Remember you can help your docs know what level their conversation...

Hi Terry, Welcome to Grace. 

I saw this exact post somewhere else months back and the only response was to a lab.  I hope that doesn't happen here, we don't allow...

Recent Comments

JOIN THE CONVERSATION
Hi Stan, It's good to hear…
By JanineT GRACE … on Fri, 12/01/2023 - 07:14
Thank you Stan, for your kind words.
By dbrock on Thu, 11/30/2023 - 11:55
Glad to know you're moving…
By JanineT GRACE … on Mon, 11/27/2023 - 11:27
Thank you very much for your…
By rutbats on Mon, 11/27/2023 - 08:07